Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia

Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia

Abstract Ulotaront (SEP‐363856) is a trace amine–associated receptor 1 agonist with 5‐HT1A agonist activity in phase III development for the treatment of schizophrenia. The efficacy of ulotaront is not mediated by blockade of D2 or 5‐HT2A receptors. The aim of this study was to evaluate the populati...

Full description

Bibliographic Details
Main Authors:	Gerald R. Galluppi, Daniel G. Polhamus, Jeannine M. Fisher, Seth C. Hopkins, Kenneth S. Koblan
Format:	Article
Language:	English
Published:	Wiley 2021-10-01
Series:	CPT: Pharmacometrics & Systems Pharmacology
Online Access:	https://doi.org/10.1002/psp4.12692

Similar Items

Evaluation of OCT2‐mediated drug–drug interactions between ulotaront and metformin in subjects with schizophrenia
by: Guangqing Xiao, et al.
Published: (2024-04-01)

Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans
by: Yu-Luan Chen, et al.
Published: (2023-03-01)

A randomized, single‐dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia
by: Hironobu Tsukada, et al.
Published: (2023-06-01)

Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
by: Christoph U. Correll, et al.
Published: (2021-12-01)

Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy
by: Francesca Perini, et al.
Published: (2023-08-01)

Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson’s disease
by: Felix Agbo, et al.
Published: (2021-07-01)

Unlocking the Therapeutic Potential of Ulotaront as a Trace Amine-Associated Receptor 1 Agonist for Neuropsychiatric Disorders
by: Savelii R. Kuvarzin, et al.
Published: (2023-07-01)

Effect of TAAR1/5-HT1A agonist SEP-363856 on REM sleep in humans
by: Seth C. Hopkins, et al.
Published: (2021-04-01)

Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy
by: Perini, F, et al.
Published: (2023)

Population Pharmacokinetic Analysis of Cefaclor in Healthy Korean Subjects
by: Seung-Hyun Jeong, et al.
Published: (2021-05-01)

Population Pharmacokinetic Analysis of Tiropramide in Healthy Korean Subjects
by: Seung-Hyun Jeong, et al.
Published: (2020-04-01)

A new model for the population pharmacokinetics of didanosine in healthy subjects
by: L.S. Velasque, et al.
Published: (2007-01-01)

Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis
by: Pei, Q, et al.
Published: (2016)

Effects of Aripiprazole on Olanzapine Population Pharmacokinetics and Initial Dosage Optimization in Schizophrenia Patients
by: Zhang C, et al.
Published: (2024-03-01)

Population Pharmacokinetic Analysis to Support and Facilitate Switching from Risperidone Formulations to Rykindo in Patients with Schizophrenia
by: Wenyan Wang, et al.
Published: (2024-01-01)

Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects
by: Haijing Yang, et al.
Published: (2022-04-01)

Population pharmacokinetics of Amisulpride in Chinese patients with schizophrenia with external validation: the impact of renal function
by: Anning Li, et al.
Published: (2023-09-01)

Conversation analysis, psychopathology and subjective experience in patients with schizophrenia
by: V. Lucarini, et al.
Published: (2021-04-01)

Glibenclamide population pharmacokinetic/pharmacodynamic modeling in South African type 2 diabetic subjects
by: Rambiritch V, et al.
Published: (2016-09-01)

Population pharmacokinetic modeling of ilaprazole in healthy subjects and patients with duodenal ulcer in China
by: Mengyang Yu, et al.
Published: (2024-01-01)

Population Pharmacokinetic/Pharmacodynamic Modeling of Depot Testosterone Cypionate in Healthy Male Subjects
by: Youwei Bi, et al.
Published: (2018-04-01)

Population pharmacokinetics
by: Milovanović Jasmina R., et al.
Published: (2005-01-01)

Pharmacokinetic, Pharmacokinetic/Pharmacodynamic, and Safety Investigations of Lefamulin in Healthy Chinese Subjects
by: Yingying Hu, et al.
Published: (2023-08-01)

The effect of azithromycin on ivermectin pharmacokinetics--a population pharmacokinetic model analysis.
by: Ahmed El-Tahtawy, et al.
Published: (2008-01-01)

Population pharmacokinetic modeling of glibenclamide in poorly controlled South African type 2 diabetic subjects
by: Rambiritch V, et al.
Published: (2016-07-01)

PB2053: POPULATION PHARMACOKINETICS OF PEGCETACOPLAN IN HEALTHY SUBJECTS AND PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
by: Haili Ping, et al.
Published: (2023-08-01)

Population Pharmacokinetic/Pharmacodynamic Analysis of Nociceptive Pain Models Following an Oral Pregabalin Dose Administration to Healthy Subjects
by: Michiel J. vanEsdonk, et al.
Published: (2018-09-01)

Population Pharmacokinetic Method to Predict Within-Subject Variability Using Single-Period Clinical Data
by: Won-ho Kang, et al.
Published: (2021-02-01)

A POPULATION PHARMACOKINETIC MODELING APPROACH TO EVALUATE THE CURRENT DOSING RECOMMENDATIONS OF FAVIPIRAVIR IN EGYPTIAN SUBJECTS
by: A. Salem, et al.
Published: (2023-05-01)

Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects
by: Kirsch Lee E, et al.
Published: (2009-12-01)

Pharmacokinetics of Paroxetine Tablets in healthy Arabic Subjects
by: Jaafar Jaber Ibraheem Al-Tamimi
Published: (2016-06-01)

The Influence of Cannabidiol on the Pharmacokinetics of Methylphenidate in Healthy Subjects
by: John S. Markowitz, et al.
Published: (2022-11-01)

Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically‐based pharmacokinetic predictions
by: Stefan Willmann, et al.
Published: (2021-10-01)

A population pharmacokinetic and pharmacokinetic‐pharmacodynamic analysis of vupanorsen from phase I and phase II studies
by: Jae Eun Ahn, et al.
Published: (2023-07-01)

Pharmacokinetic Parameters of Quinine in Healthy Subjects and in Patients with Uncomplicated Malaria in Nigeria: Analysis of Data using a Population Approach
by: Ayorinde Adehin, PhD, et al.
Published: (2019-01-01)

Subjective burden on spouses of schizophrenia patients
by: Surekha Kumari, et al.
Published: (2009-01-01)

Objective Versus Subjective Effort in Schizophrenia
by: Isabel Kreis, et al.
Published: (2020-07-01)

Population Pharmacokinetics of Primaquine in the Korean Population
by: Woo-Yul Lee, et al.
Published: (2021-05-01)

Mapping synaptic pathology within cerebral cortical circuits in subjects with schizophrenia
by: Robert Sweet, et al.
Published: (2010-06-01)

Comprehensive assessment of exposure to clozapine in association with side effects among patients with treatment-resistant schizophrenia: a population pharmacokinetic study
by: Nobuyuki Nomura, et al.
Published: (2021-05-01)